Market Value Added (MVA)
Market value added (MVA) is the difference between a firm fair value and its invested capital. MVA is a measure of the value a company has created in excess of the resources already committed to the enterprise.
MVA
Illumina Inc., MVA calculation
US$ in millions
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 Fair value of debt. See details »
2 Invested capital. See details »
| Item | Description | The company |
|---|---|---|
| MVA | Illumina Inc. market (fair) value less invested capital. | Illumina Inc. MVA decreased from 2018 to 2019 but then increased from 2019 to 2020 exceeding 2018 level. |
MVA Spread Ratio
Illumina Inc., MVA spread ratio calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Market value added (MVA)1 | 67,858) | 39,432) | 39,840) | 30,279) | 22,346) | |
| Invested capital2 | 4,907) | 4,997) | 3,989) | 3,596) | 2,874) | |
| Performance Ratio | ||||||
| MVA spread ratio3 | 1,382.87% | 789.11% | 998.68% | 841.95% | 777.45% | |
| Benchmarks | ||||||
| MVA Spread Ratio, Competitors4 | ||||||
| AbbVie Inc. | 172.70% | 236.51% | — | — | — | |
| Amgen Inc. | 343.98% | 341.92% | — | — | — | |
| Bristol-Myers Squibb Co. | 109.83% | 90.05% | — | — | — | |
| Danaher Corp. | 172.97% | 135.15% | — | — | — | |
| Eli Lilly & Co. | 778.02% | 601.09% | — | — | — | |
| Gilead Sciences Inc. | 125.56% | 226.14% | — | — | — | |
| Johnson & Johnson | 363.07% | 335.85% | — | — | — | |
| Merck & Co. Inc. | 292.93% | 328.56% | — | — | — | |
| Moderna Inc. | 1,322.35% | 1,719.94% | — | — | — | |
| Pfizer Inc. | 116.68% | 95.96% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 508.24% | 460.29% | — | — | — | |
| Thermo Fisher Scientific Inc. | 232.26% | 171.11% | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 MVA. See details »
2 Invested capital. See details »
3 2020 Calculation
MVA spread ratio = 100 × MVA ÷ Invested capital
= 100 × 67,858 ÷ 4,907 = 1,382.87%
4 Click competitor name to see calculations.
| Performance ratio | Description | The company |
|---|---|---|
| MVA spread ratio | The ratio of MVA to invested capital. It measures the efficiency with which investors’ capital investment has translated into a franchise value and into an aggregate net present value premium. | Illumina Inc. MVA spread ratio deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level. |
MVA Margin
Illumina Inc., MVA margin calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Market value added (MVA)1 | 67,858) | 39,432) | 39,840) | 30,279) | 22,346) | |
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Performance Ratio | ||||||
| MVA margin2 | 2,095.02% | 1,112.96% | 1,195.33% | 1,100.24% | 931.69% | |
| Benchmarks | ||||||
| MVA Margin, Competitors3 | ||||||
| AbbVie Inc. | 391.08% | 446.12% | — | — | — | |
| Amgen Inc. | 550.26% | 575.79% | — | — | — | |
| Bristol-Myers Squibb Co. | 232.86% | 345.41% | — | — | — | |
| Danaher Corp. | 507.10% | 438.18% | — | — | — | |
| Eli Lilly & Co. | 778.57% | 578.77% | — | — | — | |
| Gilead Sciences Inc. | 259.24% | 321.38% | — | — | — | |
| Johnson & Johnson | 432.99% | 396.88% | — | — | — | |
| Merck & Co. Inc. | 349.01% | 376.50% | — | — | — | |
| Moderna Inc. | 1,368.57% | — | — | — | — | |
| Pfizer Inc. | 289.28% | 224.34% | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 495.20% | 382.11% | — | — | — | |
| Thermo Fisher Scientific Inc. | 441.03% | 352.63% | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 MVA. See details »
2 2020 Calculation
MVA margin = 100 × MVA ÷ Revenue
= 100 × 67,858 ÷ 3,239 = 2,095.02%
3 Click competitor name to see calculations.
| Performance ratio | Description | The company |
|---|---|---|
| MVA margin | The ratio of MVA to sales. It measures how efficiently and prodigiously sales translate into franchise value. | Illumina Inc. MVA margin ratio deteriorated from 2018 to 2019 but then improved from 2019 to 2020 exceeding 2018 level. |